{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"45","value":"20"},{"groupId":"OG001","lowerLimit":"35","upperLimit":"44","value":"43"},{"groupId":"OG002","lowerLimit":"15","upperLimit":"42","value":"37"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"Time in months until \\>25% increase in serum IgM from nadir","dispersionType":"Full Range","groups":[{"description":"* Ibrutinib administered orally once daily for 48 cycles\n* Ulocuplumab administered intravenously at 400mg for Cycle 1 on Days 1, 8, 15, and 22. Ulocuplumab administered IV at 800mg for Cycles 2-6 on Days 1 and 15.","id":"OG000","title":"Phase 1 Dose Level 1: Ibrutinib + Ulocuplumab 400mg Cycle 1 and 800mg Cycles 2-6"},{"description":"* Ibrutinib administered orally once daily for 48 cycles\n* Ulocuplumab administered intravenously at 400mg for Cycle 1 on Days 1, 8, 15, and 22. Ulocuplumab administered IV at 800mg for Cycles 2-6 on Days 1 and 15.","id":"OG001","title":"Phase 1 Dose Level 2: Ibrutinib + Ulocuplumab 800 mg Cycle 1 and 1200mg Cycles 2-6"},{"description":"* Ibrutinib administered orally once daily for 48 cycles\n* Ulocuplumab administered intravenously at 800mg for Cycle 1 on Days 1, 8, 15, and 22. Ulocuplumab administered IV at 1200mg for Cycles 2-6 on Days 1 and 15.","id":"OG002","title":"Phase 1 Dose Level 3: Ibrutinib + Ulocuplumab 800mg Cycle 1 and 1600mg Cycles 2-6"}],"paramType":"MEDIAN","populationDescription":"Of the 13 participants enrolled, only 1 participant confirmed disease progression during the study period. Median PFS was not reached. The median follow-up time before participants follow-up was terminated for each participant is reported.","reportingStatus":"POSTED","timeFrame":"Response and progression status evaluated at each cycle day 1, starting at Cycle 2 Day 1 through Cycle 48, and every 12 weeks during follow-up for up to 2 years after end of treatment","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}